Hunan Er-Kang Pharmaceutical Co., Ltd. Class A

Hunan Er-Kang Pharmaceutical Co., Ltd. Class A

SSZSE:300267
2.73
CNY
-0.06
(-2.15%)
-0.18EPS
6.72BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Hunan Er-Kang Pharmaceutical Co., Ltd. Class A carries a market capitalization of 6.72B, placing it among publicly traded companies globally. Its enterprise value stands at 6.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.72B
Enterprise Value6.39B

Share Statistics

As of September 30, 2026, Hunan Er-Kang Pharmaceutical Co., Ltd. Class A has 2.06B shares outstanding.

Shares Outstanding2.06B

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 6.07, and the price-to-book ratio stands at 1.65.

PS Ratio6.07
PB Ratio1.65
P/TBV Ratio1.78

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 5.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.39B versus a market cap of 6.72B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.78

Financial Position

As of September 30, 2026, Hunan Er-Kang Pharmaceutical Co., Ltd. Class A maintains a current ratio of 2.06, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.51, indicating elevated leverage, while an interest coverage ratio of -39.24 demonstrates limited ability to service its debt obligations.

Current Ratio2.06
Quick Ratio1.01
Debt / Equity17.51
Debt / EBITDA-2.13
Interest Coverage-39.24

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 869,799.04 in revenue per employee across its workforce of 1,271.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee869,799.04
Employee Count1,271.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Hunan Er-Kang Pharmaceutical Co., Ltd. Class A recorded 39.54M in income tax expense. The company reported a pretax loss of -329.86M and -346.97M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax39.54M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hunan Er-Kang Pharmaceutical Co., Ltd. Class A's stock has declined approximately 29.82% over the past 52 weeks. The 50-day moving average sits at 3.09, while the 200-day moving average is 3.57.

52-Week Price Change-29.82%
50-Day Moving Average3.09
200-Day Moving Average3.57

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hunan Er-Kang Pharmaceutical Co., Ltd. Class A generated 1.11B in revenue and converted that into -346.97M in net income, yielding earnings per share of -0.18. EBITDA reached -329.82M, while operating income came in at 61.16M.

Revenue1.11B
Gross Profit322.69M
Operating Income61.16M
Pretax Income-329.86M
Net Income-346.97M
EBITDA-329.82M
EBIT-329.82M
Earnings Per Share (EPS)-0.18

Balance Sheet

CNY

As of September 30, 2026, Hunan Er-Kang Pharmaceutical Co., Ltd. Class A holds 960.00M in cash and equivalents against 702.40M in total debt, resulting in a net debt position of -290.82M. Total book value stands at 4.08B, with working capital of 1.01B providing operational flexibility.

Cash & Cash Equivalents960.00M
Total Debt702.40M
Net Debt-290.82M
Equity (Book Value)4.08B
Book Value Per Share1.98
Working Capital1.01B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-237.03M

Margins

Over the twelve months ended September 30, 2026, Hunan Er-Kang Pharmaceutical Co., Ltd. Class A posted a gross margin of 29.19, reflecting its pricing power and cost economics. The operating margin of 5.53 and net profit margin of -31.39 provide insight into operational efficiency.

Gross Margin29.19
Operating Margin5.53
Pretax Margin-29.84
Profit Margin-31.39
EBITDA Margin-29.83

Dividends & Yields

Over the twelve months ended September 30, 2026, Hunan Er-Kang Pharmaceutical Co., Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of -2.52 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.86, meaning Hunan Er-Kang Pharmaceutical Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Payout Ratio-2.52
Shareholder Yield-0.86

Stock Splits

Hunan Er-Kang Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 10, 2016 with a 1:2 split ratio.

Last Split Date5/10/2016
Split Ratio1:2

Scores

As of September 30, 2026, Hunan Er-Kang Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 4.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.70